Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Loop Capital Maintains Hold on Workday, Raises Price Target to $180

Loop Capital Maintains Hold on Workday, Raises Price Target to $180

Loop Capital analyst Yun Kim maintains Workday (NASDAQ:WDAY) with a Hold and raises the price target from $160 to $180.

byBenzinga Newsdesk

February 28, 2023

1 minute read

Loop Capital analyst Yun Kim maintains Workday (NASDAQ:WDAY) with a Hold and raises the price target from $160 to $180.

UBS Maintains Buy on Euronet Worldwide, Raises Price Target to $135

By Benzinga Newsdesk

February 9, 10:50 AM

UBS analyst Rayna Kumar maintains Euronet Worldwide (NASDAQ:EEFT) with a Buy and raises the price target from $131 to $135.

EEFT

Carl Icahn Released Open Letter To The Shareholders Of Illumina

By Happy Mohamed

March 15, 1:14 PM

https://carlicahn.com/icahn-responds-to-illuminas-obfuscations/ Icahn Responds to Illumina's Obfuscations Dear Fellow Illumina Shareholders:

ILMN

News

‘Google says it won’t promote as many employees to senior roles this year, citing a slowdown in growth’ -Business Insider

By Benzinga Newsdesk

March 6, 4:24 PM

https://www.businessinsider.com/google-reducing-senior-staff-promotions-growth-slowdown-2023-3

GOOG

Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott’s Next-Gen Abalation Catheter

By Vandana Singh

May 19, 1:23 PM

Stereotaxis Inc (NYSE: STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE: ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' <

ABT

Loop Capital Maintains Hold on Workday, Raises Price Target to $180

Related Posts

UBS Maintains Buy on Euronet Worldwide, Raises Price Target to $135

Carl Icahn Released Open Letter To The Shareholders Of Illumina

‘Google says it won’t promote as many employees to senior roles this year, citing a slowdown in growth’ -Business Insider

Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott’s Next-Gen Abalation Catheter